Valsts: Austrālija
Valoda: angļu
Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)
Lignocaine hydrochloride
Specialites Septodont Pty Ltd
Medicine Registered
1 BAXTER 0.4% W/V LIGNOCAINE HYDROCHLORIDE IN 5% W/V GLUCOSE INTRAVENOUS INFUSION NAME OF MEDICINE Lignocaine Hydrochloride Lignocaine Hydrochloride is designated chemically as 2-diethylaminoaceto-2’,6’-xylidide hydrochloride monohydrate. C 14 H 22 N 2 O,HCI,H 2 O (CAS registry number: 6108-05-0) Structural Formula: DESCRIPTION BAXTER 0.4% W/V LIGNOCAINE HYDROCHLORIDE IN 5% W/V GLUCOSE INTRAVENOUS INFUSION is a clear, colourless, non-pyrogenic and sterile solution. COMPOSITION Each 500 mL of the solution contains: Lignocaine Hydrochloride (monohydrate) BP 2 grams Anhydrous Glucose BP 25 grams Water for Injections BP QS Solution Hydroxide BP for pH adjustment This solution does not contain a bacteriostatic agent or buffer. The pH range of the solution is 3.5 to 6.0. The approximate osmolality of the solution is 306 mOsm. 500 mL of the solution provides approximately 398 kJ (95 kcal) PHARMACOLOGY Lignocaine Hydrochloride exerts an anti-arrhythmic effect by increasing the electrical stimulation threshold of the ventricle during diastole. Lignocaine is considered a Class 1b (membrane-stabilising) anti-arrhythmic agent acting by direct interference with depolarisation of the cardiac membrane by blocking fast inward current of sodium into cardiac cells, which shortens action potential duration. Lignocaine controls ventricular arrhythmias by suppressing: 1. automaticity in the His-Purkinje system, and 2. spontaneous depolarisation of the ventricles during diastole. 2 In usual therapeutic doses, Lignocaine Hydrochloride produces no change in myocardial contractility, in systemi Izlasiet visu dokumentu